All Activity

I think that thanks for the valuabe information and insights you have so provided here. 모바일맞고

Very informative post! There is a lot of information here that can help any business get started with a successful social networking campaign. 인디고 게임

A clear and informative article that keeps readers engaged from start to finish. The presentation style is simple, practical, and easy to follow. During my search for Escort in South Ex your content appeared more structured and insightful than many other sources.

Hello, I have browsed most of your posts. This post is probably where I got the most useful information for my research. Thanks for posting, maybe we can see more on this. Are you aware of any other websites on this subject. แทงบอล

I think this is an informative post and it is very useful and knowledgeable. therefore, I would like to thank you for the efforts you have made in writing this article. แทงบอล

You completed a few fine points there. I did a search on the subject and found nearly all persons will go along with with your blog. แทงบอล

Your authoring on content pertaining to corporate sensibility is commendable. Superior working skills, and I anticipate your Survival race forthcoming writings on this subject.

“Kudos to President Trump for stepping up and taking the lead on this. PTSD is really a killer among veterans.” By Rebecca Rivas, Missouri Independent Missouri state Rep. Dave Griffith has spent the last five years digging into research on how psychedelic-assisted therapy has helped veterans struggling with post-traumatic stress disorder and depression. This May marked the end of his final legislative session in the House, and he pushed one last time for legislation to allow clinical trials of psychedelic-assisted therapy in Missouri. In the final days of session, the bill stalled in the Missouri Senate, after passing with overwhelming support in the House. “I’m not going to be there next year, I’m term-limited out,” said Griffith, a Republican who served as chairman of the House Veterans and Armed Forces Committee. “It’s really passing the torch to a lot of the other veterans that are on the Veterans Committee and those that see the value in it.” He was hopeful when he saw an announcement from the U.S. Department of Veterans Affairs last week for a new clinical trial to evaluate the safety and efficacy of methylenedioxymethamphetamine-assisted therapy, or MDMA-assisted therapy. MDMA is a synthetic substance made in a lab, according to the department, and it’s also called “ecstasy” or “molly” in recreational use. “Kudos to President Trump for stepping up and taking the lead on this,” said Griffith of Jefferson City. “PTSD is really a killer among veterans. If you listen to the testimony that’s been taking place over the last five years just in the Missouri House alone, the life change that it’s had for them is a really compelling reason why something like this would work.” The new trial comes after Trump signed an executive order in April titled, “Accelerating Medical Treatments for Serious Mental Illness.” The order aims to increase clinical trial participation and accelerate innovative research models and drug approvals for psychedelic drugs. It orders the secretary of health and human services to allocate at least $50 million to support and partner with state governments “that have enacted or are developing programs to advance psychedelic drugs for serious mental illnesses.” Without passing legislation, Missouri will miss out on this opportunity, said Republican state Rep. Matthew Overcast of Ava. Overcast was hopeful Trump’s April order would’ve helped “grease the wheels” on legislation he and state Rep. Richard West sponsored this year to require the state to conduct a study on psilocybin- and ibogaine-assisted therapy. “There’s been a lot of federal moving on things that the states have been reluctant to move on here in the last couple of months,” Overcast said. “So that’s exciting.” According to the VA’s announcement, the department is involved in 19 other active clinical trials focused on psychedelic therapies for mental health conditions that are supported by more than $23 million in external funding. The new trial, titled “A Randomized Controlled Trial of MDMA-Assisted Therapy for PTSD and Alcohol Use Disorder in U.S. Veterans,” will enroll approximately 80 veterans and compare outcomes between those receiving MDMA-assisted therapy and those receiving identical psychotherapy with an active placebo. The VA is coordinating with the U.S. Food and Drug Administration and intends to share data from the trial with FDA. The trial will take place at VA Providence Healthcare System, and recruit veterans from the Providence, Rhode Island, campus and VA Connecticut Healthcare System in West Haven, Connecticut. Trump’s executive order states that for over 20 years there have been more than 6,000 veteran suicides per year, and the current veteran suicide rate is more than twice as much as the non-veteran adult population. Individuals, it says, suffering from major depressive disorder and substance abuse disorder, among other serious mental illnesses, can relapse or not fully respond to standard medical and psychiatric therapies. “Despite massive federal investment into researching potential advancements in mental health care and treatment, our medical research system has yet to produce approved therapies that promote enduring improvements in the mental health condition of these most complex patients,” the order states. “Innovative methods are needed to find long-term solutions for these Americans beyond existing prescription medications.” Missouri veterans John and Kara Grady, who own a hemp store in Rosebud wholeheartedly agree with the statement, they said. And they’d love to see Missouri veteran healthcare systems taking part in the clinical trials already underway. “President Trump’s really been opening up the research for the veteran community,” John Grady said, “If you look at the numbers…we’ve lost more to mental health than we’ve lost to wars.” The lack of movement on legislation for psychedelic-assisted therapy is among the reasons John Grady is running for state representative, against incumbent state Rep. Bruce Sassmann in the Republican primary. “If you disagree with Trump on all kinds of things, at least he’s addressing this issue right here that pertains to veterans,” Grady said. “Hopefully, we can stop that number, stop that flow of our precious veterans dying just at their own hands because they don’t have treatment.” This story was first published by Missouri Independent. The post Missouri GOP Lawmakers Hope Trump’s Psychedelics Order Boosts Efforts To Allow Military Veteran Access In The State appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Very useful info. Hope to see more posts soon!. เว็บแทงบอล

Wow i can say that this is another great article as expected of this blog.Bookmarked this site.. slot88

I am impressed. I don't think Ive met anyone who knows as much about this subject as you do. You are truly well informed and very intelligent. You wrote something that people could understand and made the subject intriguing for everyone. Really, great blog you have got here. wopslot

This is very educational content and written well for a change. It's nice to see that some people still understand how to write a quality post! เว็บแทงบอลออนไลน์

Awesome article, it was exceptionally helpful! I simply began in this and I'm becoming more acquainted with it better! Cheers, keep doing awesome! แทงบอลมือถือ

Your content is nothing short of brilliant in many ways. I think this is engaging and eye-opening material. Thank you so much for caring about your content and your readers. สมัครแทงบอล

I have read your article, it is very informative and helpful for me.I admire the valuable information you offer in your articles. Thanks for posting it.. เว็บแทงบอลออนไลน์

“For many veterans, the battle does not end when they come home. Too many carry the invisible wounds of service.” By Ben Solis, Michigan Advance Can a psychedelic drug with heavy side-effects and anecdotal evidence as a treatment for addiction become a wonder drug for veterans facing opioid substance abuse and post-traumatic stress disorders? House Republican state Rep. Jaime Green of Richmond wants to find out, and she wants to use opioid settlement dollars to fund necessary clinical trials—a proposal that might meet some resistance from her Democratic colleagues. Members of the House Families and Veterans Committee discussed Greene’s House Bill 6020 on Tuesday. The committee included testimony from proponents of ibogaine as a therapeutic addiction and trauma drug. The committee took testimony only and did vote on Greene’s bill. Ibogaine is currently outlawed in the United States and is considered a Schedule I controlled substance. It is a potent psychedelic with a prolonged experience sometimes lasting more than 12 hours. Those who testified on Tuesday said the drug is physically and mentally intense, as an ibogaine experience has been likened to Indigenous ancient spirit journeys with waking visions. It also carries heavy cardiovascular risks, and requires attentive medical monitoring by licensed professionals when used in a clinical setting. Much of the research being conducted into ibogaine as a therapeutic drug has been done in other nations that have allowed trials, like Mexico. Greene, a former U.S. Navy cryptologist, said she has not tried the therapy, but has heard of its potential at conferences. “For many veterans, the battle does not end when they come home. Too many carry the invisible wounds of service, post-traumatic stress, traumatic brain injury, depression, chronic pain, substance abuse disorder,” Greene told the committee. “In some cases opioid dependence begins with an injury, a prescription to manage the pain or the trauma. So, Michigan has a responsibility to stand with the men and women who serve this country, and that means honoring their service with more than words.” Greene’s bill would create an ibogaine grant program supporting research to see if the psychedelic is effective in treating substance use disorders and other conditions, like trauma-related mental illnesses. If approved as written, HB 6020 would give the Michigan Department of Health and Human Services authority to establish a consortium of other states, drug manufacturers, health facilities and research-focused universities to conduct the research. An ibogaine research fund would be established to drive dollars to the program with a proposed $50 million appropriation. The House Fiscal Agency notes that the fund would be created by the state Department of Treasury. The $50 million appropriation would come from the Michigan Opioid Healing and Recovery Fund—the state’s restricted account that holds a portion of the $1.8 billion received by Michigan from the national opioid settlement of a class-action lawsuit. That last bit could prove controversial and might make some of Greene’s colleagues on the committee wary of advancing the legislation. She was adamant that the bills would not legalize ibogaine for recreational use, nor would it impact current projects being funded by the opioid settlement fund. State. Rep. Mai Xiong (D-Warren) noted that the state has barely, if ever, funded clinical trials on experimental drugs, and that the funding would largely come from dollars set aside to not only treat opioid addiction using proven methods, but to also heal the wounds communities have endured due to rampant opioid use and damage caused by the pharmaceutical industry pushing those drugs on vulnerable populations, much like veterans. Xiong argued that the funds should be used for those more proven methods and not clinical trials. Greene responded that there hasn’t been a substance like this with so much promise, and that Michigan has state of the art research facilities that have the capacity to embark necessary trials to learn if ibogaine can be put to good use. “University of Michigan is a great example of that. That is a top global research facility that we should be having here in Michigan to not just help our veterans, but also those who are addicted to opioids,” Greene said. “Why wouldn’t we want to do that? We have a fund that is supposed to be used to help people with opioid addiction. This is actually, instead of just handing out pamphlets, this actually gives them an opportunity to be able to receive healing.” Kevin Boehnke, an assistant professor in anesthesiology and the associated director of the Michigan Psychedelic Center, spoke in support of the legislation. Boehnke said the center’s mission is to advance education and research on psychedelics as medical treatments, and is currently conducting trials on cannabis among veterans with chronic pain. Boehnke added that ibogaine, which originates in West and Central Africa, has been used for centuries by native tribes, and that interest in the drug for therapies came about in the last few decades. “Unlike conventional medicines that require daily dosing, some evidence suggests that a single ibogaine administration may improve symptoms for an extended amount of time,” he said. “Despite these known restrictions, there is some scientific literature that shows some potentially compelling benefits, especially for our veteran community.” Boehnke went on to say that veterans face disproportionately higher rates of traumatic brain injury, post-traumatic stress disorder, opioid and other substance use disorders, as well as battles with chronic pain and suicide. “While current treatment options are useful for some individuals, they leave too many service members without adequate relief,” Boehnke said. Still, state Rep. Carrie Rheingans (D-Ann Arbor) remained skeptical. In a separate interview with Michigan Advance, Rheingans said she was unsure that the parameters of the opioid settlement fund allowed for clinical trials on addiction treatment drugs. She also said that most legislators have no experience doing clinical research and that they often don’t understand what goes into it. “They don’t know how much it is to do it right, and to get scientific evidence,” Rheingans said. “It may sound like a good idea to spend some opioid settlement dollars to try and learn more about treating veteran PTSD. … I think that the anecdotes that we heard and the personal stories demonstrate that ibogaine can be a miracle for some people with their conditions. I’m not saying that that’s not true, but in order to prove it scientifically, we need multiple years of clinical trials, and those are best financed through federal funding sources.” Rheingans said it would be more appropriate for the federal National Institute of Health or the U.S. Department of Veterans Affairs to step up and fund the research. She also criticized her Republican colleagues for suggesting that the state fund the research, considering federal sources could have been an option if they didn’t see recent massive cuts under the administration of President Donald Trump. As to whether the settlement funds could be used for clinical trials, Rheingans said she believes that would be less a question for Michigan’s lawmakers and more so for Attorney General Dana Nessel. She also noted that the Legislature created a legislative opioid advisory council to weigh in on appropriations of settlement dollars. “They have published multiple reports with multiple recommendations. None of their recommendations include clinical trials for a new drug, but they do include things like recovery housing or legalizing syringe access programs…or decriminalizing fentanyl test stripes,” Rheingans said, emphasizing that she has separate bills introduced to address those areas. “If we’re going to spend $50 million of opioid settlement funds, we should spend it on recovery housing or other allowable uses, such as paying for clinicians to go get education to learn how to treat opioid use disorder.” This story was first published by Michigan Advance. Photo courtesy of Scamperdale. The post Michigan Lawmakers Debate Bill To Fund Psychedelic Research Using Opioid Settlement Dollars appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

We have sell some products of different custom boxes.it is very useful and very low price please visits this site thanks and please share this post with your friends. แทงบอล

We have sell some products of different custom boxes.it is very useful and very low price please visits this site thanks and please share this post with your friends. แทงบอล

Clear explanations and a reader-friendly structure throughout the article. It makes the topic easy to follow. While browsing Lodhi Colony Escort your site appeared reliable, informative, and well-organized.

i never know the use of adobe shadow until i saw this post. thank you for this! this is very helpful. koi toto

Great job on this guide. The content is concise, practical, and covers everything needed without being overwhelming. IPTV Quebec

A coalition of anti-marijuana groups and a cannabis-focused biopharmaceutical corporation are asking a federal appeals court to overturn a judge’s dismissal of their lawsuit challenging a new Trump administration initiative to cover up to $500 worth of hemp-derived products each year for eligible Medicare patients. Last month, Judge Trevor N. McFadden dismissed the challenge to the program that’s implemented by the Centers for Medicare & Medicaid Services (CMS) that focuses largely on CBD but also allows a certain amount of THC in products. He ruled that prohibitionist groups and activists, led by Smart Approaches to Marijuana (SAM), as well as a cannabis-focused biopharmaceutical corporation MMJ International Holdings and its subsidiaries, “have not established standing to bring this case.” Now, the plaintiffs are appealing to the U.S. Court of Appeals for the District of Columbia Circuit. “Notice is hereby given that Plaintiffs Smart Approaches to Marijuana, Cannabis Industry Victims Educating Litigators, Hillsborough County Anti-Drug Alliance, MMJ International Holdings, Inc., MMJ Biopharma Cultivation, Inc., and MMJ Biopharma Labs, Inc. hereby appeal to the United States Court of Appeals for the District of Columbia Circuit from the judgment of this court entered on May 22, 2026 in favor of Defendants against said Plaintiffs,” the short document filed on Friday says. SAM CEO Kevin Sabet said in a press release that “this fight is far from over, and we will not stand by while CMS allows for non-FDA-approved products to be given out to seniors.” “This program puts CMS in bed with Big Tobacco and Big Weed, and it puts American seniors at risk,” he argued. “CMS has a mandate to promote public health, and this program would degrade it. This move would not only put seniors at risk but also send the wrong message to the American people about the safety of these products, which have been found to have a whole host of negative side effects.” In April, lawyers for Health and Human Services Sec. Robert F. Kennedy Jr. and CMS Director Mehmet Oz filed a brief arguing that the anti-cannabis organizations that filed the suit against the Medicare hemp coverage policy do not have standing to bring the case. Outside of the challenge to the CMS hemp program, SAM and MMJ filed separate lawsuits challenging the Trump administration’s move to federally reschedule marijuana. Beyond the advocacy organizations and MMJ, the CMS hemp case involves individual plaintiffs, including anti-marijuana lawyer David Evans, who claims he had standing to challenge the new Substance Access Beneficiary Engagement Incentive (BEI) as a Medicare recipient. Previously, McFadden had rejected the plaintiffs’ request for a temporary restraining order to halt the program from launching on April 1. Notably, the government’s motion to dismiss the case says it was prepared in part by Matthew Zorn, a lawyer for HHS who before taking on the federal job led numerous cases suing government agencies on behalf of plaintiffs seeking marijuana and drug policy reform. The CMS initiative comes after President Donald Trump signed an executive order in December calling on the attorney general to finalize a rule federally rescheduling marijuana, which is now underway, that also contained components to “improve access” to full-spectrum CBD products. Under the program, inhalable preparations are not allowed, and products can contain no more than 0.3 percent delta-9 THC by dry weight and can have up to 3 milligrams of total THC per serving. The THC limit could potentially change if a law the president signed late last year takes effect as scheduled this November. That policy would strictly limit the types of cannabis products that are currently permitted under the 2018 Farm Bill that Trump signed in his first term, expressly prohibiting hemp derivatives containing more than 0.4 milligrams of total THC per container. This week, the White House called on Congress to take action to amend the planned ban to maintain legal access to hemp-derived full-spectrum CBD products. In a brief in the CMS hemp lawsuit, federal agencies noted that “CMS does not pay for hemp products under the BEI.” “The participating provider furnishes eligible products at its own cost, subject to the $500 annual cap per beneficiary. The BEI operates within the shared-savings framework that defines the underlying models. If a provider’s investment in beneficiary engagement reduces the beneficiary’s total cost of care, the provider and CMS share in the resulting savings. If it does not, the provider absorbs the loss. No new federal appropriation is involved. No new entitlement is created. The BEI is, at its core, a decision by willing providers that a particular intervention can reduce downstream claims.” Meanwhile, the White House Office of Management and Budget recently held a series of meetings about a Food and Drug Administration (FDA) CBD products enforcement policy. FDA also issued guidance making clear that it does not intend to interfere with implementation of the Medicare hemp-derived products coverage plan. CMS separately finalized a rule that will allow coverage of some hemp products as specialized, non-primarily health-related benefits through Medicare Advantage plans. Read the filing appealing the dismissal of the lawsuit challenging the Medicare hemp program below: Photo courtesy of Kimzy Nanney. The post Anti-Marijuana Groups And Pharma Company Ask Court To Revive Lawsuit Challenging Medicare Hemp Coverage Program appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Virginia officials in the administration of Gov. Abigail Spanberger (D) and lawmakers who sponsored a bill to legalize recreational marijuana sales that the governor vetoed last month have met recently to discuss the possibility of enacting the reform through budget legislation that is due to be passed soon. The sides are getting closer to reaching a deal, several sources said. “The negotiation with the governor has been very fruitful and it is clear that we have made a great deal of progress,” Del. Paul Krizek (D), who sponsored the House of Delegates version of the cannabis sales legislation, told Marijuana Moment on Friday. A spokesperson for Spanberger said the governor “has made clear that she continues to support setting up a legal retail marketplace for cannabis that prioritizes the health and safety of Virginians, protects communities and consumers and operates with clear enforcement and regulatory authority.” The governor and the sponsors of the legalization legislation “share these same goals, and she looks forward to moving this across the finish line together,” the spokesperson told Marijuana Moment. Lawmakers passed the cannabis sales bills in March, but the governor then suggested changes to the legalization proposal—including delaying the start date for sales by six months, increasing taxes and instituting new criminal penalties for cannabis consumers. The legislature in April declined to take up the amendments during a one-day reconvened session, however, effectively rejecting them. Spanberger then issued a veto. Spanberger herself has sat down in recent days with Krizek and Sen. Lashrecse Aird (D), who sponsored the Senate version of the legislation, two sources familiar with the negotiations told Marijuana Moment. Krizek also met on Thursday with an administration official to discuss the issue, the sources, who asked not to be named, said. Full details of a potential compromise on the issue between lawmakers and the governor are not yet clear, but sources indicated that the timeline for launching the cannabis market would have to be moved back at least somewhat from the date included in the now-vetoed bill. They also suggested that it is unlikely any new penalties would be as harsh as those previously proposed by the governor. Aird did not immediately respond to Marijuana Moment’s request for comment for this story. Other areas of disagreement between the cannabis legislation as passed by lawmakers and the governor’s proposed amendments that will need to be negotiated before a final deal is reached include tax rates, the number of dispensaries that will be allowed to operate and legal possession limits for consumers. Following Spanberger’s veto, top lawmakers have been openly discussing the possibility of including provisions to legalize adult-use cannabis sales in still-outstanding budget legislation that they are due to pass by July 1. The effort to keep the issue alive was a topic of discussion earlier this week at the first meeting of the legislature’s Joint Commission to Oversee the Transition of the Commonwealth into a Cannabis Retail Market since the governor’s move to kill the previous proposal to regulate adult-use marijuana sales. The governor, meanwhile, is continuing to try to publicly explain her veto—including by saying it is her view that “taking a little bit longer” to launch the market is not something she sees as “negative” because it is more important to get the details right than to do it fast. A recent survey found that bipartisan majorities of Virginia voters wanted Spanberger to sign the cannabis legislation into law, and that they specifically disagreed with her desire to slow the launch timeline for legal sales. The governor recently acknowledged in a separate interview that “a lot of people are not pleased” with her veto of the cannabis legislation. “Friends and family are displeased as well,” she said. Spanberger has repeatedly responded to criticism of her cannabis amendments from the bill sponsors and advocates by saying the suggested changes came after she spoke to the leaders of other states that have already implemented adult-use marijuana markets. A spokesperson for Spanberger declined to name any other governors she talked to about cannabis in response to a question from Marijuana Moment, however. The governor separately recently sought to explain her veto in an earlier interview, reiterating that she supports launching a legal cannabis market but worried about what she called a “rushed timeline” and “far more stores across Virginia” than she thinks are appropriate. Prior to vetoing the cannabis commerce bill, the governor did sign separate legislation to provide resentencing relief for people with past cannabis convictions. Personal marijuana possession and home cultivation of marijuana has been legal in Virginia since 2021, but then-Gov. Glenn Youngkin (R) twice vetoed bills to provide consumers with a way to legally purchase regulated adult-use cannabis. Aird and Krizek, the sponsors of the legalization bills, had urged colleagues to vote against the governor’s amendments—even if that meant risking a veto from Spanberger when the legislation returned to her desk, which has now occurred. Here are the other key details of the cannabis bills—SB 542 and HB 642—as approved by lawmakers and with the governor’s suggested amendments: Lawmakers voted to allow adults to be able to purchase up to 2.5 ounces of marijuana in a single transaction, or up to an equivalent amount of other cannabis products as determined by regulators. That would represent an increase from the limit in current law of 1 ounce. The governor, however, wanted the amount increased to only 2 ounces. Under the legislature’s plan, legal sales could begin on January 1, 2027, but the governor proposed to push that back to July 1, 2027. Lawmakers voted to impose an excise tax of 6 percent on cannabis sales as well as a 5.3 percent retail sales and use tax, while allowing municipalities to set an additional local tax of up to 3.5 percent. The governor’s plan was largely the same, though it would have increased the excise tax to 8 percent starting on July 1, 2029. Under the legislation as approved by lawmakers, revenue would have been distributed to the Cannabis Equity Reinvestment Fund (30 percent), early childhood education (40 percent), the Department of Behavioral & Developmental Health Services (25 percent) and public health initiatives (5 percent). The governor, however, wanted to put all revenue into the general fund while earmarking it “for purposes such as early childhood education, behavioral health, public health awareness, prevention, treatment, and recovery services, workforce development, reentry, indigent criminal defense, and targeted reinvestment in historically disadvantaged communities.” The Virginia Cannabis Control Authority would have overseen licensing and regulation of the new industry, and would have also taken on oversight of hemp, which is currently under the Department of Agriculture and Consumer Services. Local governments could not have opted out of allowing marijuana businesses to operate in their area. Delivery services would have been allowed. Serving sizes would have been capped at 10 milligrams THC, with no more than 100 mg THC per package. The governor proposed to make public marijuana use a class 4 criminal misdemeanor instead of civil violation punishable by a $25 fine as under current law. She also wanted to make possessing cannabis by people under the age of 21 a class 1 misdemeanor, punishable with a mandatory minimum fine of $500 or 50 hours of community service, as well as the suspension of drivers licenses for at least six months. Illegally selling or distributing 50 pounds or more of marijuana would have been a class 2 felony punishable by life in prison. The governor sought to eliminate support for the Cannabis Equity Reinvestment Fund. Existing medical cannabis operators could have entered the adult-use market if they pay a licensing conversion fee that was set at $10 million. Cannabis businesses would have had to establish labor peace agreements with workers. As passed by lawmakers, the bill would have directed a legislative commission to study adding on-site consumption licenses and microbusiness cannabis event permits that would allow licensees to conduct sales at venues like farmers markets or pop-up locations, but the governor proposed to remove that language. A coalition of cannabis reform organizations sent the governor a letter urging her not to veto the sales legalization legislation even though her amendments were rejected. “Together, these bills address the real issues surrounding cannabis in the Commonwealth today: an already-existing, unregulated marijuana market operating openly across the state while consumers, communities, and law enforcement are left without the protections of a legal framework,” the groups wrote. “Let’s be clear: these bills do not create a marijuana market in Virginia. That market already exists,” the letter said. “What these bills do is replace today’s predatory and unaccountable illicit operators with a regulated marketplace, enforceable rules, oversight, product safeguards, age verification, and the strict consumer safety standards already in use for Virginia medical cannabis.” The letter was signed by Virginia NORML, Marijuana Justice, Virginia Cannabis Association, Marijuana Policy Project and other groups. Separately, a coalition of hemp businesses that joined with a major alcohol retailer in asking Spanberger to veto the marijuana bill before she did so said the move presents an “opportunity” to craft better cannabis policy. Meanwhile, the governor signed several other reform bills this session—including measures to protect the parental rights of marijuana consumers and allow patients to access medical cannabis in hospitals. The post Virginia Lawmakers And Governor Meet To Discuss Marijuana Sales Legalization Compromise That Could Pass This Month appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Congratulations to Erica Fuller on being recognized as Tokeativity's Member of the Month! Your dedication, authenticity, and contributions to the community are truly inspiring. It's wonderful to see your hard work and passion being celebrated. Wishing you continued success and looking forward to seeing all the amazing things you'll accomplish next! You can also take note about AI servcies like Ai receptionist Evansville and Virtual receptionist Kansas City

A congressional panel has approved annual spending legislation that would affirmatively block federal workers’ compensation programs from covering medical marijuana—even in light of the Trump administration’s move to reschedule cannabis. The House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies on Friday voted 11-7 to advance the Fiscal Year 2027 bill that contains several marijuana- and drug policy-related provisions. One section says that no funding provided to the Department of Labor under the measure can be used to “authorize, provide, reimburse, or otherwise recognize marijuana or any cannabis-derived substance as a compensable medical treatment or benefit” under any federal workers’ compensation program—”regardless of any change in the scheduling of marijuana” under the Controlled Substances Act (CSA). “SEC. 532. None of the funds made available by this Act may be used by the Department of Labor, including the Office of Workers’ Compensation Programs, to authorize, provide, reimburse, or otherwise recognize marijuana or any cannabis-derived substance as a compensable medical treatment or benefit under any Federal workers’ compensation program, including the Federal Employees’ Compensation Act, regardless of any change in the scheduling of marijuana under the Controlled Substances Act. Nothing in this section shall be construed to require or permit reimbursement for marijuana under any Federal workers’ compensation program.” Trump administration in April announced that it was moving state-licensed medical cannabis, as well as any cannabinoid products approved by the Food and Drug Administration, to Schedule III, where WNBA’s prohibition would presumably no longer apply. Broader reclassification of marijuana to Schedule III will be the topic of a hearing scheduled to begin later this month. The bill that is advancing also contains a rider that blocks the use of funds for “any activity that promotes the legalization of any drug or other substance included in schedule I” of the Controlled Substances Act. “SEC. 509. (a) None of the funds made available in this Act may be used for any activity that promotes the legalization of any drug or other substance included in schedule I of the schedules of controlled substances established under section 202 of the Controlled Substances Act except for normal and recognized executive-congressional communications. (b) The limitation in subsection (a) shall not apply when there is significant medical evidence of a therapeutic advantage to the use of such drug or other substance or that federally sponsored clinical trials are being conducted to determine therapeutic advantage.” The provision has been included in federal spending legislation since the 1990s. Rep. Alexandria Ocasio-Cortez (D-NY) in past years has attempted to get that language deleted by arguing that it impedes research on psychedelics, but her amendments have been defeated. Finally, the legislation as approved by the subcommittee contains a rider restricting the use of funds for syringe exchange programs and a prohibition on support for safe consumption sites for illegal drugs. “SEC. 525. Notwithstanding any other provision of this Act, no funds appropriated in this Act shall be used to purchase sterile needles or syringes for the hypodermic injection of any illegal drug: Provided, That such limitation does not apply to the use of funds for elements of a program other than making such purchases if the relevant State or local health department, in consultation with the Centers for Disease Control and Prevention, determines that the State or local jurisdiction, as applicable, is experiencing, or is at risk for, a significant increase in hepatitis infections or an HIV outbreak due to injection drug use, and such program is operating in accordance with State and local law: Provided further, That none of the funds appropriated in this Act may be used for the operation of a supervised drug consumption facility that permits the consumption onsite of any substance listed in schedule I of section 202 of the Controlled Substances Act (21 U.S.C. 812).” Earlier this week, the House Appropriations Committee approved a separate spending bill and attached report that directs federal officials to continue requiring government employees and safety-sensitive workers such as truck drivers and airline pilots to be drug tested for marijuana, “regardless of any future changes to the legal status or scheduling.” The panel also voted last month to advance a provision that, if enacted, would prevent federal officials from taking further steps to carry out marijuana rescheduling. That funding bill also contains an updated version of a longstanding rider that since 2014 has protected state medical cannabis programs from federal interference. The committee report attached to that legislation also contains a number of cannabis-related provisions, including one calling on the Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA) to address the “proliferation of Federally unregulated ingestible, inhalable, and topical products that contain intoxicating cannabinoids” and that “threaten consumer safety.” Separately, the House Appropriations Committee recently approved a spending bill and an attached report that expresses concerns about health risks from cannabis-derived products, while also encouraging research into the therapeutic benefits of psychedelics. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile in Congress, the House last month approved amendment to let military veterans receive recommendations for medical marijuana through their doctors at the Department of Veterans Affairs (VA) The full House also recently passed a Farm Bill with provisions aimed at aiding industrial hemp producers—but without any language to delay or alter the federal recriminalization of hemp THC products that’s scheduled to take effect later this year. The post Congressional Committee Votes To Block Medical Marijuana From Being Covered Under Workers’ Comp For Federal Employees appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net